The most common adverse events with didanosine are [[diarrhea]], [[nausea]], [[vomiting]], [[abdominal pain]], [[fever]], [[headache]] and [[rash]]. Peripheral [[neuropathy]] occurred in 21-26% of participants in key didanosine trials.<ref name="Videxpi" />

 


 
[[Pancreatitis]] is rarely observed but has caused occasional fatalities, and has [[black box warning]] status. Other reported serious adverse events are retinal changes, [[optic neuritis]] and alterations of liver functions. The risk of some of these serious adverse events is increased by drinking alcohol.

 


 
In February 2010, the United States Food and Drug Administration issued a statement that patients using Didanosine (Videx) are at risk for a rare

 
but potentially fatal liver disorder, non-cirrhotic portal hypertension.<ref>http://hosted.ap.org/dynamic/stories/U/US_HIV_DRUG_LIVER_RISKS?SITE=KYB66&SECTION=HOME&TEMPLATE=DEFAULT</ref>

 

